CORDIS
EU research results

CORDIS

English EN

PAN EBOLA VACCINE INNOVATIVE APPROACH – Sofia ref.: 116088

Project information

Grant agreement ID: 116088

Status

Ongoing project

  • Start date

    1 June 2017

  • End date

    31 May 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 17 731 397,75

  • EU contribution

    € 6 189 570

Coordinated by:

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France

Objective

Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.

A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

Address

3 Avenue Victoria
75000 Paris

France

Activity type

Research Organisations

EU Contribution

€ 1 297 406

Participants (13)

HEINRICH-PETTE INSTITUT LEIBNIZ INSTITUT FUER EXPERIMENTELLE VIROLOGIE

Germany

EU Contribution

€ 81 250

EXCELLGENE SA

Switzerland

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 1 040 108

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS

Switzerland

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 533 332

OLIGOVAX

France

EU Contribution

€ 863 000

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN

Germany

EU Contribution

€ 182 500

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

France

EU Contribution

€ 603 125

VAXEAL RESEARCH

France

UNIVERSITE D'ABOMEY-CALAVI

Benin

EU Contribution

€ 566 312

IFAKARA HEALTH INSTITUTE TRUST

Tanzania

EU Contribution

€ 502 000

ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

Italy

EU Contribution

€ 273 650

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 246 887

Project information

Grant agreement ID: 116088

Status

Ongoing project

  • Start date

    1 June 2017

  • End date

    31 May 2023

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 17 731 397,75

  • EU contribution

    € 6 189 570

Coordinated by:

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France